A 16-week follow up to saroglitazar treatment at a dose 4 mg per day revealed its beneficial effects in reducing ALT, insulin resistance, atherogenic dyslipidemia and the hepatic fat amount. This evidence concerns the gene GPT and Insulin resistance.